[Comment] Head-to-head comparison of balloon-expandable transcatheter heart valves

Transcatheter aortic valve intervention (TAVI) is a well established therapy for severe aortic stenosis, demonstrating excellent mid-term outcomes in patients across all surgical risk groups.1,2 Valve durability and repeatability are key concepts when considering young (ie, aged <75 years) patients with low surgical risk and increased life expectancy, who might therefore outlive their bioprosthetic valve.3 Short-frame balloon-expandable transcatheter heart valves (THVs) are suitable in most anatomies and offer potential for a second TAVI procedure in most cases.